Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.64 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.64 |
| ▸ | HSP90AA1 | P07900 | 15/20 | 0.61 |
| ▸ | MET | P08581 | 1/20 | 0.60 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21644599 | 0.90 | HSP90AA1 (0.54) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL21644524 | 0.87 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL21644654 | 0.86 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL30779628 | 0.86 | CYP3A4 (0.67) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL21644535 | 0.85 | CYP3A4 (0.74) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL487753 | 0.84 | CYP3A4 (0.47) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL487931 | 0.84 | HSP90AA1 (0.47) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL487997 | 0.83 | HSP90AA1 (0.58) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL21644563 | 0.82 | HSP90AA1 (0.48) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 | |
| SCHEMBL21644510 | 0.80 | HSP90AA1 (0.72) | CYP3A4CYP2C9CYP2C19CYP2B6HSP90AA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111164074-B | Heat shock protein 90 inhibitors | 台北医学大学 | 2024-02-02 | — | — | CN | disclosed |
| US-11479528-B2 | Heat shock protein 90 inhibitors | TAIPEI MEDICAL UNIVERSITY (TW) | 2022-10-25 | — | — | US | disclosed |
| CN-111164074-A | Heat shock protein 90 inhibitor | 台北医学大学 | 2020-05-15 | — | — | CN | disclosed |
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | TAIPEI MEDICAL UNIVERSITY (TW) | 2020-02-06 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-8106057-B2 | Dihydroxyphenyl isoindolylmethanones | ASTEX THERAPEUTICS, LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | ASTEX THERAPEUTICS LTD. (GB) | 2010-11-11 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-7754725-B2 | Dihydroxyphenyl isoindolymethanones | ASTEX THERAPEUTICS LTD. (GB) | 2010-07-13 | — | — | US | disclosed |
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| US-20080306054-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2008-12-11 | — | — | US | disclosed |
| EP-1883402-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | Astex Therapeutics Limited (GB) | 2008-02-06 | — | — | EP | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | ASTEX THERAPEUTICS, LTD. (GB) | 2007-11-08 | — | — | US | disclosed |
| WO-2006109075-A2 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286167-A1 | DIHYDROXYPHENYL ISOINDOLYLMETHANONES | HSP90AA1, HSP90AB1, HSP90AB2P | CYP3A4 2003/4885CYP2C9 3332/4885CYP2C19 2786/4885 |
| US-20070259886-A1 | (2,4-Dihydroxy-5-isopropyl-phenyl)-[5-(2-dimethylamino-ethoxy)-1,3-dihydro-isoindol-2-yl]-methanone; inhibits or modulates activity of heat shock protein Hsp90; useful for treating cancer, particularly hematopoietic tumors of lymphoid or myeloid lineage, prostate, lung, breast cancer, melanoma | HSP90AB2P, HSP90AA1, HSP90AB1 | CYP3A4 2059/4885CYP2C9 3441/4885CYP2C19 2057/4885 |
| US-20200039923-A1 | HEAT SHOCK PROTEIN 90 INHIBITORS | HSP90AB1, HSP90AB2P, HSP90AA1 | CYP3A4 4066/4885CYP2C9 4003/4885CYP2C19 4107/4885 |
| US-20080306054-A1 | Pharmaceutical Compounds | HSP90AB1, HSP90AA1, HSP90AB2P | CYP3A4 165/4885CYP2C9 80/4885CYP2C19 173/4885 |
| US-11479528-B2 | Heat shock protein 90 inhibitors | HSP90AB1, HSP90AB2P, HSP90AA1 | CYP3A4 4066/4885CYP2C9 4003/4885CYP2C19 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.